Now Available: Video Podcasts of MSK Report's Meeting Coverage

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

ACR 2007: Visit Musculoskeletal Report's dedicated ACR 2007 page for complete coverage of the American College of Rheumatology's 71st Annual Scientific Meeting, including press conference videos and interviews with presenters.

CME News Response to RA Therapy in First 3 Months Predicts Chance of Remission at 1 Year
Rheumatoid arthritis disease activity during the first 3 months of treatment predicts response at 1 year, and even partial response may "reset the baseline" for subsequent treatment...

ACR 2007: Fish Oil May Improve Symptoms and Endothelial Function in SLE
Omega-3 fish oil may reduce lupus disease activity and improve endothelial function...

ACR 2007: New Rheumatoid Arthritis B-Cell Depletor Advances in Phase II Trials
The experimental B-cell depleting small modular immunopharmaceutical (SMIP), TRU-015 has promising safety and efficacy trials in phase II RA data reported at the American College of Rheumatology...

ACR 2007: New Topical Nitroglycerin for Raynaud's Phenomenon Reported at ACR
A new topical formulation of nitroglycerine that is not absorbed systemically significantly reduced symptoms in over 40% of patients with Raynaud's phenomenon...

BioPharm Business: Trubion Reports Data From Phase IIb and Re-Treatment Studies With TRU-015 in RA Patients
Trubion Pharmaceuticals Inc, a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer, announced that TRU-015, its lead Small Modular ImmunoPharmaceutical drug candidate for the treatment of rheumatoid arthritis (RA), provided statistically significant efficacy after a single infusion of 800 mg or 1600 mg compared with placebo for a 24-week period...

To remove your e-mail address from our mailing list, please reply to this e-mail with "unsubscribe" in the subject line. For questions and comments regarding this newsletter please contact .